Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)

The de-intensification arm is designed to determine whether those with a low decipher genomic risk score (defined as less than 0.40) treated with radiation therapy alone instead of 6 months androgen deprivation therapy experience non-inferior rates of distant metastasis. The intensification arm aims to determine whether those in the high decipher genomic risk score (grater than or equal to .40) will have a superior metastasis-free survival through the addition of darolutamide with the standard radiation therapy and androgen deprivation therapy.

Criteria:

  • Prostate cancer diagnosis

Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, MidState Medical Center, Saint Vincent's Medical Center, Hartford HealthCare Medical Group - Manchester

Contacts: SVMC: Aidyn.Bergeron@hhchealth.org 475-210-4647, Hartford Region: Sierra.Cugno@hhchealth.org 860-972-4062, HOCC: Siobhan.Reilly@hhchealth.org 860-696-4958

Sponsor: NRG Oncology

Cancer Clinical Research Office